<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1562">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140824</url>
  </required_header>
  <id_info>
    <org_study_id>TJ202001SLE101</org_study_id>
    <nct_id>NCT05140824</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to&#xD;
      Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses&#xD;
      of TJ202 in Patients with Systemic Lupus Erythematosus&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>43 days post last dose for single dose</time_frame>
    <description>Evaluate the rate of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>113 days post last dose for multi- dose</time_frame>
    <description>Evaluate the rate of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic(PK) Parameters: Cmax</measure>
    <time_frame>43 days post last dose for single dose,</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic(PK) Parameters: Cmax</measure>
    <time_frame>113 days post last dose for multi- dose</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic(PK) Parameters: Tmax</measure>
    <time_frame>43 days post last dose for single dose,</time_frame>
    <description>Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic(PK) Parameters: Tmax</measure>
    <time_frame>113 days post last dose for multi- dose</time_frame>
    <description>Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic(PK) Parameters: AUC</measure>
    <time_frame>43 days post last dose for single dose,</time_frame>
    <description>AUC0-tlast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic(PK) Parameters: AUC</measure>
    <time_frame>113 days post last dose for multi- dose</time_frame>
    <description>AUC0-tlast</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Systemic Lupus Erythematosus (SLE)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TJ202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ202 injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TJ202 injection</intervention_name>
    <description>TJ202 injection</description>
    <arm_group_label>TJ202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (subjects must meet all the following criteria for inclusion in this&#xD;
        study):&#xD;
&#xD;
        Single Dose:&#xD;
&#xD;
          1. Male or female, 18-65 years old (inclusive), weight of ≥ 45 kg.&#xD;
&#xD;
          2. Definite diagnosis of systemic lupus erythematosus (see Annex 3. SLE Classification&#xD;
             Criteria by SLICC 2012 for diagnostic criteria), and an SLE disease activity index&#xD;
             (SLEDAI) score of &lt; 15 (see Annex 4. SLE Disease Activity Score [SLEDAI-2000] for&#xD;
             scoring criteria) . A positive antinucleus antibody (ANA) test result.&#xD;
&#xD;
          3. If a subject is receiving SLE treatment, a stable SLE regimen must be maintained up to&#xD;
             the date of the first dose of study drug (the permitted medications and their maximum&#xD;
             doses are as follows):&#xD;
&#xD;
               -  Glucocorticoids: prednisone 10 mg/day or other glucocorticoids with an equivalent&#xD;
                  dose. It should be stable for at least 4 weeks prior to receiving the first dose&#xD;
                  of study drug.&#xD;
&#xD;
               -  Other immunosuppressive drugs alone or in combination with glucocorticoids&#xD;
                  include the following: azathioprine (maximum dose of 100 mg/day), methotrexate&#xD;
                  (maximum dose of 15 mg/week), mycophenolate mofetil (maximum dose of 1500&#xD;
                  mg/day), tripterygium wilfordii polyglycosides (maximum dose of 60 mg/day),&#xD;
                  leflunomide (maximum dose of 20 mg/day), tacrolimus (maximum dose of 4 mg/day),&#xD;
                  ciclosporin (maximum dose of 100 mg/day). The above medications should be used&#xD;
                  for at least 12 weeks and stable for at least 4 weeks prior to receiving the&#xD;
                  first dose of study drug.&#xD;
&#xD;
               -  Hydroxychloroquine: The maximum allowable dose is 400 mg/day, and combination&#xD;
                  with the immunosuppressants listed above is allowed. It should be used for at&#xD;
                  least 12 weeks and the dose should be stable for at least 4 weeks prior to&#xD;
                  receiving the first dose of study drug.&#xD;
&#xD;
          4. The subject is willing to participate in the study and voluntarily sign the ICF.&#xD;
&#xD;
          5. Subjects of childbearing potential or subjects with a partner of childbearing&#xD;
             potential must agree to use effective contraceptive measures throughout the study&#xD;
             (except oral estrogens, estrogenic vaginal ring, etc., refer to Annex 5. Contraceptive&#xD;
             Measures, Definitions of Women of Childbearing Potential and Contraception&#xD;
             Requirements for optional contraceptive methods).&#xD;
&#xD;
             Multiple Doses: in addition to the single-dose inclusion criteria, subjects should&#xD;
             meet the following criteria&#xD;
&#xD;
          6. dsDNA antibody titer (ELISA) greater than or equal to 1.5 times the upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
        Exclusion Criteria (subjects who meet any of the following criteria will be excluded from&#xD;
        the study):&#xD;
&#xD;
          1. Central nervous system (CNS) diseases: active central nervous system lupus (including&#xD;
             epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident,&#xD;
             encephalitis, or CNS vasculitis), visual disturbance, cranial neuropathy within 60&#xD;
             days prior to screening, with intervention required.&#xD;
&#xD;
          2. Renal disorders: nephrotic syndrome (protein urine &gt; 3.5 g/24 h) within 30 days prior&#xD;
             to screening, or requiring protocol-prohibited medications (such as intravenous&#xD;
             cyclophosphamide) for active nephritis, or requiring hemodialysis or high-dose&#xD;
             glucocorticoids such as prednisone of ≥ 100 mg/day (or other glucocorticoids with&#xD;
             equivalent doses).&#xD;
&#xD;
          3. Cardiovascular disorders: history of acute myocardial infarction, or unstable angina,&#xD;
             severe arrhythmia (multifocal frequent ventricular premature beats, ventricular&#xD;
             tachycardia, ventricular fibrillation), etc. over the past six months; New York Heart&#xD;
             Association (NYHA) Class III-IV (see Annex 6. NYHA for details).&#xD;
&#xD;
          4. Subjects with a known history of moderate or severe persistent asthma (assessed by the&#xD;
             Asthma Severity Scale of the National Heart, Lung, and Blood Institute [NHLB]) within&#xD;
             the past 5 years, or who currently have uncontrolled asthma (of any grade).&#xD;
&#xD;
          5. Asthma and specific dermatitis, etc. requiring glucocorticoid-dependent therapy&#xD;
             (except topical glucocorticoids).&#xD;
&#xD;
          6. Infections, requiring treatment for acute or chronic infections, as follows:&#xD;
&#xD;
               -  Treatment with any inhibitory therapy currently for chronic infections (e.g.,&#xD;
                  tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, zoster virus&#xD;
                  and atypical mycobacteriosis);&#xD;
&#xD;
               -  Hospitalization for an infection within 60 days prior to dosing;&#xD;
&#xD;
               -  Treatment with anti-infective drugs (antibacterials, antivirals, antifungals, or&#xD;
                  antiparasites) by parenteral administration (IV or IM) 60 days prior to dosing.&#xD;
&#xD;
               -  Subjects with mycobacterium tuberculosis, including those with a positive &quot;T-cell&#xD;
                  spot test for tuberculosis infection (T-SPOT)&quot; (latent tuberculosis infection:&#xD;
                  except those who have completed tuberculosis prophylaxis for 4 weeks before their&#xD;
                  first dose), or those with a positive imaging result.&#xD;
&#xD;
          7. Subjects with positive results from any of the following tests: hepatitis B surface&#xD;
             antigen (HBs Ag), hepatitis B core antibody (HBc Ab), hepatitis C virus antibody (HCV&#xD;
             Ab), human immunodeficiency virus antibody (HIV Ab), or treponema pallidum antibody&#xD;
             (TPPA). Patients who tested positive for hepatitis B core antibody (HBc Ab) but&#xD;
             negative for HBV-DNA should be excluded.&#xD;
&#xD;
          8. Hematological system diseases or hematology abnormalities: subjects with previous or&#xD;
             current hematological system diseases (including but not limited to: myelofibrosis,&#xD;
             anemia aplastic aregenerative, leukemia, lymphoma, etc.), hematology with hemoglobin &lt;&#xD;
             100 g/L, white blood cells &lt; 3.0 × 109/L, granulocytes &lt; 2.5 × 109/L, lymphocytes &lt;&#xD;
             0.8 × 109/L, or platelets &lt; 100 × 109/L.&#xD;
&#xD;
          9. Abnormal liver function: aspartate aminotransferase (AST) or alanine aminotransferase&#xD;
             (ALT) or glutamyl transpeptidase (GGT) values &gt; 2 times ULN; or total bilirubin or&#xD;
             alkaline phosphatase (ALP) values &gt; 1.5 times ULN.&#xD;
&#xD;
         10. Abnormal renal function: creatinine (Cr) or urea nitrogen (BUN) values &gt; 1.5 times the&#xD;
             upper limit of normal (ULN); pre-screening estimated glomerular filtration rate (eGFR)&#xD;
             ≤ 60 mL/min. Calculate eGFR values using the MDRD formula: eGFR (mL/min × 1.73 m2) =&#xD;
             175 × blood creatinine ([Scr (mg/dL)])-1.154 × age-0.203 × sex (M = 1, F = 0.742).&#xD;
&#xD;
         11. Cancer: history of malignancy within the last 5 years.&#xD;
&#xD;
         12. Transplant: history of major organ transplant (e.g., heart, lung, kidney, liver) or&#xD;
             hematopoietic stem cell or bone marrow transplant.&#xD;
&#xD;
         13. Female subjects with a positive serum pregnancy test or currently lactating.&#xD;
&#xD;
         14. History of major surgery (craniotomy, thoracotomy, or laparotomy) or presence of&#xD;
             unhealed wounds, ulcers, or fractures within 4 weeks prior to the first dose of study&#xD;
             treatment.&#xD;
&#xD;
         15. Targeted drug therapy: rituximab within 180 days before the first dose; any drug&#xD;
             therapy targeting T-lymphocytes, B-lymphocytes, cytokines or receptors [e.g.,&#xD;
             belimumab, telitacicept, abatacept, etc.] within 90 days before the first dose; JAK&#xD;
             inhibitors within 30 days before the first dose; other investigational drugs for less&#xD;
             than 5 half-lives.&#xD;
&#xD;
         16. Subjects who have participated in any other clinical trials (including receiving&#xD;
             investigational vaccines) or received treatment with invasive and investigational&#xD;
             medical devices within 3 months before inclusion, or are being enrolled into an&#xD;
             interventional and investigational study.&#xD;
&#xD;
         17. Stable doses of anticoagulant or antiplatelet drugs used before randomization that&#xD;
             exceeded regular doses or was increased within 7 days before dosing.&#xD;
&#xD;
         18. Immunosuppressants:&#xD;
&#xD;
               -  Have received any of the following treatments within 90 days prior to screening:&#xD;
                  Intravenous immunoglobulin (IVIG);Use of high-dose glucocorticoids such as&#xD;
                  prednisone ≥ 100 mg/day;Plasma exchange, leukopheresis;Cyclophosphamide.&#xD;
&#xD;
               -  Use of immunomodulatory agents such as thymosin within 30 days prior to&#xD;
                  screening.&#xD;
&#xD;
         19. Vaccination within 30 days prior to the first dose of study treatment.&#xD;
&#xD;
         20. Use of traditional Chinese medicinal products or herbal preparations such as total&#xD;
             glucosides of white paeony capsules, zhengqinfengtongning and colquhounia root tablets&#xD;
             within 30 days prior to the first dose of study treatment.&#xD;
&#xD;
         21. Drug abusers determined by medication history inquiries, including morphine, ketamine,&#xD;
             tetrahydrocannabinolate, methamphetamine, dimethyldioxymethamphetamine and cocaine.&#xD;
&#xD;
         22. Subjects who have consumed more than 14 units of alcohol/week (1 unit of alcohol = 360&#xD;
             mL of beer, 150 mL of wine, or 45 mL of liquor) within 3 months prior to screening, or&#xD;
             who cannot abstain from alcohol during the trial, as determined by history inquiries.&#xD;
&#xD;
         23. Other conditions: including laboratory abnormalities, history of any other disease&#xD;
             (e.g., recent history of septicemia), clinically significant unstable or uncontrolled&#xD;
             acute or chronic conditions unrelated to SLE (e.g., acute pneumonia, pulmonary&#xD;
             arterial hypertension, diabetic ketoacidosis, acute pancreatitis, etc.). In the&#xD;
             opinion of the investigator, the above conditions may confound the study results or&#xD;
             place the subject at an inappropriate risk. Thus, the subjects who experience the&#xD;
             conditions above are not suitable for participation in this study.&#xD;
&#xD;
         24. Subjects who are unsuitable for participation in this clinical study for any other&#xD;
             reasons as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary Ma</last_name>
    <phone>021-60575740</phone>
    <email>mary.ma@i-mabbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hosptial Zhejiang University School of Medicine</name>
      <address>
        <city>Zhejiang</city>
        <state>Hangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Xue, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Bo Jiang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weiguo Wan, Doctor</last_name>
      <email>Wgwan1969@sina.com</email>
    </contact>
    <investigator>
      <last_name>Weiguo Wan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Evaluate the Safety, Tolerability</keyword>
  <keyword>A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

